On Sept. 1, 2020, HDT Bio received a notice of award from the National Institute of Allergy and Infectious Disease at the National Institutes of Health. The approved contract provided $8.2M in support of pre-clinical and clinical activities to be conducted by HDT and collaborators to accelerate development of HDT-301 a COVID-19 vaccine candidate.

Further describing the vaccine candidate, Reed said, “HDT-301 represents the latest in RNA vaccine technology. Reflecting on the broader collaborations, Reed observed, “We have a long-standing history of working with NIAID and are eager to join with them and our other collaborators on this program.”

HDT Bio’s mission is to bring immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications. HDT Bio simultaneously works to integrate therapeutic approaches for first-in-class medicines while building on decades of development experience with well-established pharmaceutical ingredients. The resulting products are poised to significantly improve the lives of millions of people worldwide and to provide access to lifesaving therapies for underserved populations.